## **LONZA GROUP AG**

ISIN: CH0013841017 WKN: 1384101 Asset Class: Stock



## **Company Profile**

Lonza Group AG is engaged in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment offers small molecule drug substances and intermediates related services. The Cell and Gene segment includes the Cell and Gene Technologies and Bioscience businesses. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.

Financial figures, Fiscal year: from 01.	01. to 31.12.					
Financial figures	<b>2023</b> Assets Liabilities and equity		2022 Assets Liabilities and equity		<b>2021</b> Assets Liabilities and equity	
Current assets	4,885,000,000		5,712,000,000		5,933,000,000	
Common stock capital		74,000,000		74,000,000		74,000,000
Fixed assets	12,198,000,000		11,845,000,000		10,758,000,000	
Equity capital of a company		9,512,000,000		10,665,000,000		9,823,000,000
Cash and cash equivalents	1,468,000,000		1,339,000,000		1,582,000,000	
Accrued liabilities		425,000,000		407,000,000		465,000,000
Other assets	-		-		-	
Current liabilities		2,763,000,000		3,080,000,000		2,370,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		4,808,000,000		3,812,000,000		4,498,000,000
Different income		-		-		-
Other liabilities		752,000,000		793,000,000		731,000,000
Total assets	17 083 000 000	17 083 000 000	17 557 000 000	17 557 000 000	16 691 000 000	16 691 000 000

Different income		-		-		-
Other liabilities		752,000,000		793,000,000		731,000,000
Total assets	17,083,000,000	17,083,000,000	17,557,000,000	17,557,000,000	16,691,000,000	16,691,000,000
Balance notes						
				2023	2022	2021
Accounting standard				IFRS	IFRS	IFRS
Employees				18,000	17,494	16,218
Equity ratio				56.03%	61.13%	59.29%
Debt-equity ratio				78.47%	63.58%	68.66%
Others						
				2023	2022	2021
Tax Expense Rate				16.81%	15.91%	10.53%

## **LONZA GROUP AG**

ISIN: CH0013841017 WKN: 1384101 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	6,717,000,000	6,223,000,000	5,409,000,000
Net income	654,000,000	1,215,000,000	674,000,000
EBIT	888,888,600	1,540,536,600	872,597,400
Operating income before taxes	803,000,000	1,446,000,000	788,000,000
Cash Flow	1,419,000,000	1,039,000,000	1,220,000,000
Net interest income	-70,000,000	-67,000,000	-69,000,000
Research and development expenses	105,000,000	95,000,000	90,000,000
Income taxes	135,000,000	230,000,000	83,000,000
Result from investments in subsidaries, associates and other	-13,000,000	2,000,000	-28,000,000
Revenues per employee	379,958	362,196	339,588

<b>Board of Directors</b>	
Annalia - Kablerana	Manufacture of the analysis to the state of the same
Angelica Kohlmann	Member of the administrative board
Marion Helmes	Member of the administrative board
Olivier Verscheure	Member of the administrative board
Roger Nitsch	Member of the administrative board
Barbara Richmond	Member of the administrative board
Christoph Mäder	Member of the administrative board
Jürgen B. Steinemann	Member of the administrative board

Members of Management Board			
Albert M. Baehny	Chairman of Managing Board		
Christian Seufert	Member of Executive Committee		
Daniel Palmacci	Member of Executive Committee		
Gordon Bates	Member of Executive Committee		
Jean-Christophe Hyvert	Member of Executive Committee		
Maria Soler Nunez	Member of Executive Committee		
Philippe Deecke	Member of Executive Committee		
Ulrike Kaeppler	Member of Executive Committee		